An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia

  • Kaplan, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

Effective start/end date14/09/2113/09/26


  • Immune Thrombocytopenia
  • Pharmacokinetics
  • treatment safety
  • treatment efficacy
  • phase 1 and 2 study